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Identification and Characterization of Small Molecules That Inhibit
Intracellular Toxin Transport䌤†
Jose B. Saenz, Teresa A. Doggett, and David B. Haslam*
Departments of Pediatrics and Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110

Shiga toxin (Stx), cholera toxin (Ctx), and the plant toxin ricin are among several toxins that reach their
intracellular destinations via a complex route. Following endocytosis, these toxins travel in a retrograde direction
through the endosomal system to the trans-Golgi network, Golgi apparatus, and endoplasmic reticulum (ER). There
the toxins are transported across the ER membrane to the cytosol, where they carry out their toxic effects. Transport
via the ER from the cell surface to the cytosol is apparently unique to pathogenic toxins, raising the possibility that
various stages in the transport pathway can be therapeutically targeted. We have applied a luciferase-based
high-throughput screen to a chemical library of small-molecule compounds in order to identify inhibitors of Stx. We
report two novel compounds that protect against Stx and ricin inhibition of protein synthesis, and we demonstrate
that these compounds reversibly inhibit bacterial transport at various stages in the endocytic pathway. One
compound (compound 75) inhibited transport at an early stage of Stx and Ctx transport and also provided
protection against diphtheria toxin, which enters the cytosol from early endosomes. In contrast, compound 134
inhibited transport from recycling endosomes through the Golgi apparatus and protected only against toxins that
access the ER. Small-molecule compounds such as these will provide insight into the mechanism of toxin transport
and lead to the identification of compounds with therapeutic potential against toxins routed through the ER.
cellular transport of Stx (46). Since that time, a number of
toxins, in addition to Ctx and ricin, have likewise been found to
transit through the ER en route to the cytoplasm. Given the
importance of these pathways to intoxication by diverse pathogenic agents, a number of investigations have been directed at
identifying host molecules involved in toxin transport. Previous
studies aimed at identifying essential components of the retrograde pathways of Stx, ricin, and Ctx have focused largely on
the Rab family of small GTP-binding proteins. Members of the
Rab family cycle between their GTP- and GDP-bound forms,
which are related to their functions as regulators of vesicular
traffic (53). Standard genetic approaches involving overexpression of dominant-negative mutants or small interfering RNA
knockdowns of various Rabs have revealed the complexity of
toxin trafficking pathways. Inhibition of Rab7 and Rab9, which
are involved in lysosome targeting pathways, had no effect on
ricin and Stx trafficking (21, 47). In contrast, inhibition of
Rab6a⬘, involved in endosome-to-TGN transport, inhibited Stx
transport from endosomes through the Golgi apparatus (17,
33, 59) but had no effect on ricin transport or intoxication (8).
Similarly, overexpression of a dominant-negative Rab11, implicated in transport from recycling endosomes to the TGN,
resulted in impaired Stx transport but had no effect on ricin
(21, 60). Rab22, like Rab6a⬘, has been implicated in endosome-to-TGN transport, though inhibition of Rab22 function
has had inconsistent effects on retrograde toxin transport (34).
Though these pathways still remain poorly characterized, the
sequential retrograde progression utilized by these toxins has
translated into a unique system for probing host endocytic
mechanisms.
In an effort to dissect and inhibit the stepwise trafficking of
Stx, we have developed a quantitative and highly sensitive,
high-throughput luciferase-based assay to screen a library of
small-molecule compounds for their ability to block Stx-medi-

Bacterial and plant toxins are significant agents of human
disease and potential vehicles for bioterrorism. Though their
intracellular targets are diverse, a common and essential step
in their virulence is the ability to reach the cytosol, where most
toxins exert their enzymatic effects. The bacterial exotoxins
Shiga toxin (Stx) and cholera toxin (Ctx), as well as the plant
toxin ricin, have drawn particular interest for their unique
retrograde transport following endocytosis. Members of the
AB toxin group, these toxins consist of a receptor-binding B
subunit and an enzymatic A subunit. In contrast to anthrax and
diphtheria toxins, AB toxins that enter the cytosol directly from
early endosomes in a pH-dependent manner (18, 28, 35), these
membrane-bound toxins bypass the late endocytic pathway by
retrograde transport from early or sorting endosomes to the
trans-Golgi network (TGN) (14, 15, 37, 60). From the TGN,
they traffic through the Golgi apparatus to the endoplasmic
reticulum (ER), where they are subsequently translocated
through the Sec61p channel into the cytosol via ER quality
control mechanisms (49, 56, 62). It is believed that this complex retrograde transport may allow for certain essential steps
in toxin activation and transfer; Stx has been shown to be
cleaved and activated by host proteases (16). Similarly, the
ability to reach the ER may enable a chaperone-facilitated
transfer to the cytosol, as previously reported for Ctx, ricin, and
Stx (49, 52, 62, 63).
The existence of a retrograde transport pathway was first
uncovered by electron microscopic studies tracking the intra-
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MATERIALS AND METHODS
Reagents and antibodies. Small chemical compounds were purchased from
ChemDiv and reconstituted to 5-mg/ml stocks in dimethyl sulfoxide (DMSO).
All compounds were checked for purity by mass spectroscopy. Shiga-like toxin 1
and diphtheria toxin (DT) were from List Biological Laboratories, and ricin was
from Sigma. Recombinant Ctx subunit B (CtxB) labeled with Alexa Fluor 488,
Alexa Fluor 594-labeled human transferrin (Tf), SlowFade Gold mounting reagent with or without 4⬘,6⬘-diamidino-2-phenylindole (DAPI), and Alexa Fluorlabeled goat or donkey secondary antibodies against immunoglobulin G were
obtained from Molecular Probes. Rabbit anti-giantin was from Covance and
sheep anti-human TGN46 from Serotec. Dulbecco’s modified Eagle’s medium
(DMEM), Eagle’s minimum essential medium, streptomycin, and penicillin were
from BioWhittaker. Nonessential amino acids were purchased from Mediatech.
Cycloheximide, DMSO, brefeldin A (BFA), nocodazole, anisomycin, and staurosporine were from Sigma. Tran35S was purchased from MP Biomedicals, and
35
S-labeled O4 was obtained from American Radiolabeled Chemicals.
Cell culture. Vero cells were grown and maintained in DMEM supplemented
with 10% fetal calf serum (Sigma), 100 g/ml streptomycin, 100 U/ml penicillin,
and 1% nonessential amino acids at 37°C under 5% CO2.
Purification of StxB. The recombinant B subunit of Stx (StxB) was isolated
from periplasmic extracts of Escherichia coli BL21(DE3) cells (Invitrogen) containing the pT7B5-1 expression vector, as previously described (11). Briefly,
periplasmic extracts were subjected to anion-exchange chromatography on a
Q-Sepharose column (Pharmacia), and pentameric StxB was isolated following
further purification of the Q-Sepharose peak on a Superdex 75R 10/30 gel
filtration column (Pharmacia). Fractions containing StxB were identified by slot
blot (Hoefer) using a polyclonal rabbit anti-StxB antibody (11), and positive
fractions were combined and concentrated to 1 mg/ml using Ventricon Plus-20
filters (Millipore). StxB purity was verified by sodium dodecyl sulfate (SDS)polyacrylamide gel electrophoresis on a 4 to 20% Tris-HCl gel stained with
Coomassie blue. Alexa Fluor 488 and 594 conjugation was performed by following the manufacturer’s recommendations (Molecular Probes).
Luciferase-based assay for measuring protein synthesis. The luciferase-based
assay has been described previously (64). It was applied to a high-throughput
screen (HTS) of small molecules consisting of known biological compounds as
well as unknown compounds at the ICCB facility at Harvard University. The
luciferase protein has been modified by Promega by the addition of a PEST
sequence, resulting in its short intracellular half-life (44). The luciferase-PEST
cDNA was cloned into an adenovirus expression plasmid (64), and high-titer viral
stocks were generated (pAD-Luc). Vero cell monolayers were transduced with
pAD-Luc (multiplicity of infection, 200), incubated for 24 h at 37°C under 5%
CO2, and then seeded into 384-well black polystyrene plates (Corning) at 1 ⫻104
cells/well for an additional 24 h. Cells were then treated for 30 min at 37°C with
known biological compounds and unknown compounds at 5 mg/ml. Stx was
added at 1 ng/ml, and cells were incubated for an additional 4 h at 37°C. To
determine luciferase expression, the SuperLight luciferase reporter gene assay
was used according to the manufacturer’s instructions (BioAssay Systems), and
light output was detected using an LMax 1.1L luminometer (Molecular Devices).
To be considered protective, the compound must increase the luciferase signal at
least twofold above the mean observed from cells treated with toxin alone.
Compounds maintaining luciferase expression levels in the presence of cycloheximide alone (100 g/ml) were excluded from further analysis.
Radioactive amino acid incorporation assay. Experiments measuring radioactive 35S incorporation were used to confirm positive hits from the luciferasebased HTS. This assay was adapted to a multiwell format to enable testing on a

large number of samples. Vero cells were cultured overnight at 37°C under 5%
CO2 in 96-well plates at 2.5 ⫻ 104 cells/well, whereupon the medium was removed and replaced with either prewarmed medium (plus 0.5% [vol/vol] DMSO)
or a medium containing a compound. Following a 1-h incubation at 37°C, toxin
was added to wells in triplicate, and cells were shifted to 37°C for an additional
4 h. The medium was then removed from all wells and replaced with a medium
containing Tran35S-label at 10 Ci/ml. Cells were incubated at 37°C for 45 min,
washed with phosphate-buffered saline (PBS) (pH 7.4), and lysed (1 mg/ml
bovine serum albumin, 0.2% deoxycholic acid, 0.1% SDS, 20 mM Tris [pH 7.4])
at 4°C for 12 h. Proteins from the lysed cells were precipitated with trichloroacetic acid (TCA) (final concentration, 15%) and transferred to multiscreen HA
plates (Millipore), and the filters were washed with ice-cold 20% TCA. Filters
were then removed from the plate and placed in 2 ml Bio-Safe II scintillation
fluid (RPI), and 35S incorporation was quantitated using a beta counter (Beckman). Independent experiments were performed at least three times for potent
compounds, and data were analyzed using Prism software (version 4.0; 2003).
Toxin and Tf internalization. For toxin trafficking experiments, Vero cells
were grown in chamber slides (2.5 ⫻ 104 cells/chamber), treated with a medium
containing DMSO, compound, or known agents at the indicated concentrations
for 1 h at 37°C, and then placed on ice for 15 min prior to the addition of toxin.
The toxin was bound for 45 min at 4°C, followed by washing of unbound toxin
with ice-cold PBS (pH 7.4). Fresh, prewarmed medium was added, and cells were
shifted to 37°C for the indicated times to allow for toxin internalization. In Tf
trafficking experiments, cells were pretreated with compounds in serum-free
culture medium, and Tf and toxin were bound to cells at 4°C for 1 h, followed by
a shift to 22°C for 1 h. For all immunofluorescence experiments, cells were fixed
in 4% paraformaldehyde in cold PBS, permeabilized in a culture medium containing 0.1% Triton X-100, and blocked with a culture medium containing 0.1%
bovine serum albumin (wt/vol), all at room temperature. All primary antibodies
and secondary antibodies (donkey anti-immunoglobulin G labeled with Alexa
Fluor 488, 594, or 555) were diluted in blocking buffer. Cells were rinsed thoroughly in PBS prior to being mounted in SlowFade Gold reagent with or without
DAPI (Invitrogen Corp.). Fluorescence imaging used epifluorescence (Zeiss) or
confocal (Olympus) microscopy.
Cell viability assay. The viability of cells treated with a compound was evaluated using the CellTiter-Glo lumninescent cell viability assay (Promega), a
luciferase-based assay. Vero cells (5 ⫻ 104/well) were added to 96-well plates and
grown at 37°C under 5% CO2 overnight. The medium was then removed and
replaced with a prewarmed medium either with DMSO alone or with a compound, in triplicate. Following incubation at 37°C for various times, an equal
volume of CellTiter reagent (50 l) was added according to the manufacturer’s
instructions, and the light output was measured using the Lmax 1.1L luminometer. Independent experiments were performed three times.
Cloning and expression of StxB-Sulf2-His6. In order to add overlapping sulfation sites to the carboxyl terminus of StxB, the StxB gene from pNAS-13 (11)
was amplified with primers Sulf-1 (5⬘-GGTGCTCAAGGAGTATTGTGTAAT
ATGAAAAAAACATTATTAATAGC-3⬘) and Sulf-2 (5⬘-GGATTCAGCGAA
GTTATTTTTCGTGGAGAGGAACCTGAGTATGGAGAAGAGGAACCT
GAGTATGGAGAAAGCGGCCGAAAAAAGTAGGCCG-3⬘), which encodes
the two overlapping sulfation sites (Sulf2) added to StxB by Johannes et al. (22).
The amplified product was ligated into expression plasmid pCRT7-TOPO (Invitrogen). Sequencing of one such product revealed a nucleotide deletion at base
312 of the StxB coding region, such that the sulfation sites were intact and the
frameshift resulted in read-through in frame into the pCRT7 flanking sequence
encoding a V5 epitope, a histidine tag, and a stop codon. This protein was found
to be expressed at a high level from BL21(DE3) cells and was used in further
studies. The protein was expressed from BL21(DE3) cells by the addition of 0.1
M isopropyl-␤-D-thiogalactopyranoside (IPTG) (Fisher Scientific) to cultures
growing at late-log phase. After 2 h of incubation at 30°C, the bacteria were
harvested by centrifugation, and a periplasmic extract was prepared by osmotic
lysis. The material was mixed with 2 ml of nickel-nitrilotriacetic acid resin
(QIAGEN) and incubated overnight at 4°C with rocking. The resin and periplasmic extract were then applied to an empty column, and the beads were washed
with several column volumes of PBS, followed by PBS containing imidazole at 25,
50, 250, and 500 mM. The StxB-Sulf2-His protein, which remained associated
with the column at 500 mM imidazole, was released by the addition of 5 ml of 2
M imidazole in PBS. The eluted protein was dialyzed twice against PBS (pH 7.4),
aliquoted, and stored at 4°C. In order to demonstrate that addition of the
sulfation, V5, and histidine tags did not affect the binding and transport of the
toxin, StxB-Sulf2-His was labeled with Alexa Fluor 488 according to the manufacturer’s instructions (Molecular Probes). Vero cells were incubated with 1
g/ml each of StxB-Sulf2-His-Alexa Fluor 488 and wild-type StxB labeled with
Alexa Fluor 594. After binding at 4°C for 1 h, the cells were washed, warmed to
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ated inhibition of protein synthesis (64). Because Stx transport
involves a multistep progression through the cell, we predicted
that inhibitory compounds could be identified at distinct stages
along the retrograde trafficking pathway and could potentially
be directed at specific molecular targets. From an initial screen
of 14,400 small compounds, we identified several potential
inhibitors. Among these, we characterized two compounds
(compounds 75 and 134) that reversibly inhibit Shiga intoxication and act at distinct steps along the toxin trafficking pathway. Our results demonstrate the utility of a small-molecule
approach to elucidating toxin transport pathways and will lead
to the identification of novel therapeutic approaches targeting
diseases caused by ER-routed toxins.
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curves, the toxin concentration varied, while the concentration of DMSO (0.5%
[vol/vol] in control cells), compound 75 (25 M), or compound 134 (50 M) was
kept constant. Toxin IC50s were compared using the extra sum-of-squares F test
applied to the best-fit curves for the data. Differences between toxin IC50s were
considered statistically significant at a P value of ⱕ0.05 and highly statistically
significant at a P value of ⱕ0.01.

RESULTS
HTS for compounds that inhibit Stx activity in host cells.
Several toxins damage host cells by inhibiting protein synthesis.
DT and Pseudomonas exotoxin inhibit protein synthesis
through the ADP-ribosylation of elongation factor 2 (7, 41),
whereas Stx and the plant toxin ricin inhibit ribosome function
by cleaving an adenosine residue from the 60S ribosome (3, 13,
39, 40, 45). Still other toxins, such as Ctx and anthrax edema
toxin, induce increases in second-messenger levels, resulting in
cytotoxicity (6, 26, 54). In order to quantitate the effects of
various protein synthesis-inhibiting toxins on host cells, we had
previously established a luciferase-based assay that could
readily determine the susceptibilities of various cell lines to
Stx, ricin, DT, and Pseudomonas exotoxin (64). In cells constitutively expressing an mRNA encoding destabilized firefly luciferase, luciferase enzyme activity served as a surrogate measure of protein synthesis.
This assay was adapted to an HTS and applied to a screen of
small-molecule compounds that inhibit toxin susceptibility.
The ICCB facility at Harvard University contains a number of
commercial libraries consisting of synthetic and natural products. An initial screen of biological compounds with known
effects yielded positive hits such as BFA and D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) (data
not shown), two compounds previously shown to inhibit Stx
susceptibility through distinct mechanisms (25, 50) and serving
as positive controls for the detection of Stx-inhibitory compounds. In addition, the assay detected known inhibitors of the
proteasome, such as MG-132 (3). This was an expected result,
since the discriminatory power of the assay is dependent on the
rapid degradation of luciferase following translation (65).
We next screened the ChemDiv 3 library at the ICCB facility, consisting of 14,400 compounds of unknown function. The
compounds included in this library were selected for their
structural diversity, chemical stability, and “drug-like properties.” Since these compounds were commercially available and
their functions currently undefined, we reasoned that novel
inhibitors could be identified. Among these were selected the
top 1% of compounds yielding the highest luciferase signal in
the presence of toxin, all of which resulted in a signal at least
twice the baseline. Because the initial screen lacked a counterscreen to exclude compounds affecting luciferase turnover,
each compound was subsequently tested for its effect on the
luciferase signal following cycloheximide treatment. Cycloheximide-mediated inhibition of protein synthesis is independent
of intracellular transport, and its mechanism of ribosomal inactivation is distinct from that of Stx (55). Therefore, compounds that provide protection against cycloheximide-mediated inhibition of the luciferase signal must be acting in a
toxin-independent manner (e.g., by inhibiting luciferase degradation), and such compounds were excluded from further
analysis. After exclusion of compounds that affected cycloheximide-induced suppression of the luciferase signal, eight com-
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37°C for 1 h, fixed with 4% paraformaldehyde, and visualized by epifluorescence
microscopy.
Sulfation of StxB-Sulf2-His. Vero cells were seeded overnight at 37°C under
5% CO2 (1 ⫻ 106 cells/well). The next day, the medium was replaced with
serum-free DMEM lacking sulfate (Washington University Tissue Culture Support Center), and cells were incubated for an additional 3.5 h at 37°C. The
medium was replaced with sulfate-free DMEM containing DMSO or compound
for 30 min at 37°C; then it was replaced with prewarmed sulfate-free medium
containing 1 mCi/ml 35S-labeled O4 for 3 h at 37°C. Wells were washed with cold
PBS (pH 7.4) and lysed with PBS containing 1% Triton X-100. The protein
concentrations of postnuclear supernatants were determined by the bicinchoninic acid protein assay kit (Pierce), and 250 g of lysates was added to 40 l of
nickel-nitrilotriacetic acid Superflow beads and rotated at 4°C overnight. The
next day, beads were spun down at 5,000 rpm for 5 min, and the unbound fraction
was collected. Total 35S-incorporated counts were determined by measuring
radioactive counts from TCA-precipitated proteins of unbound lysates. Beads
were washed once with PBS containing 1% Triton X-100 and twice with PBS.
Beads were resuspended in imidazole (1.5 M in PBS), and eluates were denatured with 1⫻ SDS gel-loading buffer (50 mM Tris-HCl, 100 mM ␤-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% [vol/vol] glycerol) and boiled.
Eluates were resolved on a 10 to 20% Tris-HCl denaturing gel, fixed, and
developed overnight in a phosphorimager cassette.
Expression and trafficking of VSVG-GFP. Vero cells were transiently transfected with vesicular stomatis virus G protein (VSVG)-green fluorescent protein
(GFP) ts045, as previously described for other cell lines (19). Briefly, 106 Vero
cells were transfected with 20 g of pCDM8.1 expressing VSVG-GFP ts045 and
a Lipofectamine 2000 (Invitrogen) mixture in antibiotic-free medium (DMEM
with 10% fetal calf serum), followed by overnight incubation at 37°C under 5%
CO2. Cells were collected and placed in chamber slides (Lab-Tek) for an additional 8 to 10 h at 37°C before their transfer to 42°C for 12 to 16 h. Cells were
then treated with compounds or BFA (25 g/ml) in prewarmed, antibiotic-free
medium for 1 h at 42°C before being transferred to 32°C. Thirty minutes prior to
the shift to 32°C, all chambers were treated with cycloheximide (100 g/ml) to
prevent de novo protein synthesis. Cells were fixed following various incubation
times at 32°C. Fixation, permeabilization, staining, and imaging were performed
as described for toxin and Tf internalization experiments.
GFP secretion time course. A plasmid encoding enhanced GFP (EGFP) fused
at the amino terminus with the secretion signal of human neuropeptide Y (NPY)
was obtained from Richard Mains (12). The insert was released by BglII and
NotI digestion and ligated into plasmid pENTR-4 (Invitrogen) that had been
digested with BamHI and NotI. This plasmid was used as the source for insertion
of the NPY-EGFP cDNA into adenovirus expression plasmid pAD-DEST (Invitrogen) by the clonase reaction (Invitrogen). The resulting plasmid, pAD-NPYGFP, was linearized with PacI and transfected into 293A cells to prepare a
low-titer viral stock. The virus was amplified by further passage in 293A cells
until a high-titer stock was prepared. Vero cells transduced with pAD-NPY-GFP
were washed, trypsinized, and seeded into 8-well chamber slides. The next day,
the medium was replaced with a culture medium containing DMSO or the
indicated compound for 30 min at 37°C. Cycloheximide was then added at 100
g/ml, and cells were washed and fixed with 4% paraformaldehyde in PBS (pH
7.4) at various times following cycloheximide treatment. Permeabilization, staining, and imaging were performed as described for toxin and Tf internalization
experiments.
Assessment of NPY-GFP secretion. Approximately 5 ⫻ 106 Vero cells were
infected overnight at 37°C under 5% CO2 with pAD-NPY-GFP. Cells were then
washed, trypsinized, and seeded into each well of a 6-well plate (⬃1 ⫻ 106
cells/well). The next day, the medium was removed, and cells were washed twice
with serum-free medium. The medium was subsequently replaced with serumfree DMEM containing DMSO or a compound for 30 min at 37°C. Cells were all
treated with cycloheximide (100 g/ml) to inhibit de novo protein synthesis and
to synchronize NPY-GFP trafficking. At various time points following cycloheximide treatment, supernatants were collected, and GFP secretion was assessed by
an enzyme-linked immunosorbent assay (ELISA) as described in the manufacturer’s instructions (Pierce). ELISA plates were analyzed by the Gen5 software
program (BioTek) using the Synergy 2 spectrophotometer (BioTek). The mean
absorbance for control wells containing DMEM alone was subtracted from the
absorbance for each sample well before analysis.
Statistics. All statistical analyses were performed by GraphPad Prism 5. For
Fig. 1, toxin concentrations were log transformed prior to curve fitting and
statistical analyses. Toxin-response curves were generated by nonlinear regression (least-squares fit) to correspond to the observed data, and the concentration
of toxin needed to reduce protein synthesis by 50% (50% inhibitory concentration [IC50]) was calculated by using the fitted curves. For the toxin-response
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pounds with toxin-specific effects were selected for further
analysis. Notably, our subsequent screens have incorporated a
cycloheximide counterscreen in order to exclude compounds
with toxin-independent effects prior to secondary analysis (see
Fig. S1 in the supplemental material).
Secondary analysis to determine the potency and efficacy of
inhibitory compounds. The optimal protective concentration
for each identified hit was determined using a radioactive assay
for protein synthesis (11) that was modified for mediumthroughput analysis in a multiwell format (see Materials and
Methods). Since some of these compounds could exhibit nonspecific effects at increased concentrations, the lowest concentration providing significant protection against Stx compared
to the effect of the toxin on untreated Vero cells was considered to be optimal. Compounds classified as inhibitors showed
half-maximal activity between 10 and 50 M (data not shown).
Compounds were used above their half-maximal but below
their maximal concentrations for all subsequent assays (at 25
M for compound 75 and 50 M for compound 134).
The abilities of these compounds to protect against increasing Stx concentrations were expressed as the toxin IC50s (see
Materials and Methods). Using these criteria, compounds 75
and 134, at their respective optimal concentrations, exhibited
the greatest protective effects among the hits identified from
the initial screen. Both compounds showed statistically significant increases in the Stx IC50 compared to that for cells containing no compound (Fig. 1). At higher concentrations (50
M and 100 M, respectively), compounds 75 and 134 exhibited up to 1,000-fold increases in the Stx IC50 (data not shown).

Neither of these compounds affected luciferase degradation in
the presence of cycloheximide (data not shown).
An initial characterization of compounds showing highly
protective effects against Stx led us to consider whether these
compounds could protect against other toxins that inhibit protein synthesis. Compounds 75 and 134 showed similar statistically significant increases in the ricin IC50 (Fig. 1) (P ⬍ 0.01).
Protection against both Stx and ricin was also greater than the
previously observed protective effects of an overexpressed
dominant-negative mutant of Rab6, a small GTP-binding protein found to be essential to Stx transport through the Golgi
apparatus (8).
Interestingly, compound 134 failed to show a statistically
significant effect against DT-mediated protein synthesis inhibition (Fig. 1A), while compound 75 demonstrated greater
protection (Fig. 1B). Vero cells that were not treated with a
compound demonstrated a DT susceptibility profile similar to
those for Stx and ricin. Stx and ricin, following endocytosis, are
known to traffic from an endosomal compartment to the ER
via the Golgi apparatus (30). DT, however, directly accesses
the cytosol from early endosomes; the low endosomal pH is
believed to allow for a conformational change in the holotoxin
and to promote shuttling of the A moiety across the endosomal
membrane (41). The lack of protection against DT suggests
that compound 134 affects toxin transport at a point after the
early-endosome stage but has no effect on trafficking from the
plasma membrane to the early endosomal compartment. In
contrast, the protective effect of compound 75 against all three
toxins suggests that this compound affects transport mecha-
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FIG. 1. Protective effects of inhibitory compounds against Stx, ricin, and DT. (A) Compound 134 structure and demonstration that this
compound (50 M) protects against Stx- and ricin- but not DT-mediated decreases in protein synthesis. Toxin IC50s for Stx and ricin in
compound-treated cells were found to be statistically different (ⴱ, P ⬍ 0.05) from those in control cells. The DT IC50 in compound-treated cells
was not statistically different from that in control cells (P ⬎ 0.05). (B) Compound 75 structure and demonstration that this compound (25 M)
protects against Stx-, ricin-, and DT-mediated decreases in protein synthesis. Toxin IC50s for all three toxins in compound-treated cells were found
to be highly statistically different (ⴱⴱ, P ⬍ 0.01) from those in control cells. Protein synthesis levels for control (black squares) (no compound) and
compound-treated (gray triangles) Vero cells were determined using the radioactive amino acid incorporation assay as described in Materials and
Methods. The percentage of protein synthesis is expressed as the amount of radioactive amino acid incorporation in control or compound-treated
cells at a given toxin concentration as a percentage of radioactive amino acid incorporation in cells lacking toxin treatment. Toxin-response curves,
toxin IC50s, and statistical comparisons between control and compound-treated cells were calculated as described in Materials and Methods. Each
data point (mean ⫾ standard deviation) represents triplicate data at the indicated toxin concentration from one representative experiment.
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nisms common to all three pathways, presumably at an earlier
stage in endocytosis than the site of action of compound 134.
Effects of compounds 75 and 134 on toxin transport. In
order to determine the site at which inhibitory compounds
were affecting toxin activity, the endocytosis and transport of
fluorescent StxB and CtxB were examined. The retrograde
transport of protein toxins is believed to occur exclusively from
early and/or recycling endosomes (32). In order to determine
whether endocytosis and trafficking of StxB to early and recycling endosomes were affected by compound 134, StxB transport was compared to that of fluorescently labeled Tf, which is
known to accumulate in recycling endosomes at 22°C due to a
block in recycling-endosome-to-TGN transport at this temperature (33). In agreement with previous reports, StxB colocalized with Tf-positive compartments in control cells at 22°C
(Fig. 2A). StxB trafficking to Tf-positive compartments in compound 134-treated cells was not significantly different from that
in control cells, showing a similar level of colocalization with
the perinuclear recycling-endosome compartment (Fig. 2A).
Similar results were seen with CtxB, which also accumulated in
a Tf-positive perinuclear compartment. (Fig. 2B). In addition,
compound 134 did not affect the binding of StxB to the cell
surface (see Fig. S2 in the supplemental material), suggesting
that this compound was not occupying toxin receptor binding
sites or significantly decreasing receptor expression. Taken together with the relative lack of protection by compound 134
against DT-mediated protein synthesis inhibition (Fig. 1A),
these results collectively suggest that compound 134 maintains
Stx and Ctx transport to recycling endosomes.
Compound 75, like compound 134, did not inhibit StxB
binding to its receptor or decrease receptor expression (see
Fig. S2 in the supplemental material). However, treatment
with compound 75 appeared to inhibit the transport of both

StxB/CtxB and Tf to perinuclear recycling endosomes. Most of
the toxin and most of the Tf were located in peripheral vesicular structures (Fig. 2A and B), likely early endosomes. These
results, in addition to those demonstrating the effects of compound 75 on susceptibility to DT, collectively suggest that this
compound inhibits Stx and Ctx transport to recycling endosomes.
Immunohistochemical analysis of compound-treated cells
revealed morphological changes to the Golgi apparatus (see
Fig. S3 in the supplemental material). The dispersal of the
Golgi apparatus is a morphological effect that has been observed under several conditions that impair retrograde and
intra-Golgi transport (10). To exclude the possibility that the
effects of these compounds were not specific to intracellular
toxin transport, we sought to rule out processes that are known
to have effects on Golgi morphology. In particular, during the
process of apoptosis, the Golgi apparatus becomes fragmented
(9, 31, 43). In order to rule out the possibility that compounds
75 and 134 were inducing Golgi apparatus fragmentation
through apoptosis, ATP levels in compound-treated cells were
compared to those in untreated cells or cells treated with
staurosporine, a known apoptosis-inducing agent (23). Treatment with compound 75 or 134 failed to deplete ATP levels
over 24 h, in contrast to the effect observed following staurosporine treatment, suggesting that the compounds were not
cytotoxic or apoptosis inducing at the specified concentrations
over the time course studied (Fig. 3A). In addition, compoundtreated cells consistently showed a more punctate and swollen
Golgi apparatus compared to the more tubulated Golgi apparatus in staurosporine-treated cells (Fig. 3B). The Golgi morphology of compound-treated cells also differed from the characteristic Golgi architecture of cells treated with anisomycin, a
peptidyl transferase inhibitor shown to induce apoptosis in
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FIG. 2. Compound 75 impedes StxB/CtxB and Tf ligand trafficking to recycling endosomes. (A) Vero cells were first incubated with Alexa Fluor
594-labeled StxB (1 g/ml) and Alexa Fluor 488-labeled Tf (1 g/ml) for 1 h at 4°C in serum-free medium, then shifted to 22°C for an additional
hour, and finally developed for immunofluorescence, as described in Materials and Methods. In control (0.5% [vol/vol] DMSO) and compound
134-treated cells, StxB reached a perinuclear, Tf-positive compartment previously described as recycling endosomes (cross). In compound
75-treated cells, however, no perinuclear staining was observed, and Tf and StxB were confined to early endosomes (punctate staining). (B) Neither
CtxB nor Tf reached the perinuclear Tf-positive recycling endosome compartment in compound 75-treated Vero cells compared to control and
compound 134-treated cells. Results are representative of two similar experiments. Images were obtained at ⫻1,000 magnification. Blue, nuclei.
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HeLa cells (57). Other small-molecule compounds known to
affect Golgi morphology include nocodazole (10), a microtubule-disrupting agent, and BFA, a known trafficking inhibitor
that causes complete dispersal of the Golgi apparatus (24, 42).
The morphological effects of compounds 75 and 134 on the
Golgi apparatus were distinct from each of these (Fig. 3B).
Thus, the effects on the Golgi apparatus, induced by these
compounds as early as 30 min following compound treatment
(see Fig. S3 in the supplemental material), were consistently
distinct from the characteristic morphological and biochemical
changes observed with known apoptosis-inducing and Golgidisturbing agents.
As another means of determining and quantifying the effects
of compounds 75 and 134 on toxin transport from early endosomes to the TGN, sulfation of a StxB construct bearing a
tandem of C-terminal sulfation sites (StxB-Sulf2) was evaluated. Sulfation of endogenous proteins occurs in the TGN, and
sulfation of internalized StxB-Sulf2 has shown that it traffics
through this compartment (27). Trafficking of fluorescently

labeled StxB-Sulf2 showed Golgi localization similar to that of
native StxB labeled with Alexa Fluor 594 in untreated cells
(Fig. 4A) and thus could serve as the basis for a suitable assay
for toxin trafficking through the TGN. In agreement with its
effect at an early stage in toxin trafficking, compound 75 decreased StxB sulfation to 47% of the level for compoundnegative samples (Fig. 4B). By contrast, compound 134 modestly reduced sulfation (to 72% of the level for the control)
over the 3-h incubation period. Sulfation of endogenous proteins, as assessed by total 35S incorporation, was unaffected by
compound treatment, implying that the compounds were not
inhibiting sulfotransferase enzymatic activity (data not shown).
Together with previous results, these results are consistent with
compound 75 inhibiting transport at an early stage in endocytosis and compound 134 blocking transport at a post–recyclingendosome stage (including recycling-endosome-to-TGN transport).
Compounds 75 and 134 reversibly target toxin retrograde
transport. Small-molecule compounds may act by reversible or
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FIG. 3. The morphological and biochemical effects of compound treatment are distinct from those produced by apoptosis-inducing or Golgidisturbing agents. (A) Compound treatment does not affect viability, as determined by intracellular ATP levels. Vero cells were incubated with compound
75, compound 134, staurosporine, or DMSO for as long as 24 h at 37°C at the indicated concentrations. ATP levels were determined by the CellTiter-Glo
luminescent cell viability assay (see Materials and Methods). Luminescence (expressed as relative light units) is linearly related to ATP levels in viable
cells. Results (means ⫾ standard deviations) are triplicate data for each time point from one representative experiment. (B) Compound 134 produces
changes in Golgi morphology distinct from those generated by known apoptosis-inducing (staurosporine, anisomycin) or Golgi apparatus-disturbing
(nocodazole, brefeldin A) agents. Vero cells were treated for 1 h with the specified compounds at the indicated concentrations prior to incubation with
1 g/ml Alexa Fluor 488-labeled CtxB at 4°C for 1 h. Toxin was internalized for 1 h at 37°C. Cells were fixed, permeabilized, and stained with an antibody
against the Golgi marker giantin. Compound 75 produced a dispersal of the Golgi apparatus similar to that seen with compound 134 (see Fig. S3 in the
supplemental material). Blue, nuclei. Images were obtained at ⫻1,000 magnification.
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irreversible mechanisms. In general, irreversible inhibitors act
by covalent interaction with or modification of target molecules, such as through oxidation or acylation. Reversible compounds often act as competitive inhibitors of enzymatic activity
or of protein-target interactions. Morphological effects on the
Golgi apparatus produced by compound 75 or compound 134
treatment were found to be reversible. Following washout of
the compounds, the Golgi apparatus reassembled in compound-treated cells at a time point at which BFA-treated cells
maintained an altered Golgi morphology (Fig. 5A). More importantly, Vero cells lost protection against Stx following washout of either compound (Fig. 5B).
Effects of compounds on anterograde transport. The toxintrafficking pathway, proceeding from an early endosome to the
ER via the Golgi apparatus, is almost the mirror inverse of the
biosynthetic and secretory pathways. The degree of overlap
between the retrograde and anterograde pathways, however,
remains largely unresolved. Since no host molecules have been
shown to traffic from endosomes all the way to the ER, the
ability to track bacterial toxins and identify compounds that
potentially block their transport allows us to specifically probe
the retrograde pathway in its entirety.
To study the effects of these compounds on general anterograde transport, the sequential trafficking of a temperaturesensitive VSVG-GFP (ts045) fusion protein (19) in transiently
transfected Vero cells was examined. Cells kept at 42°C
showed that VSVG-GFP was confined to the ER, and a shift to
32°C allowed anterograde progression to the Golgi apparatus
by 1 h (Fig. 6). Compounds 75 and 134 did not inhibit VSVGGFP transport from the ER to the Golgi apparatus, as evidenced by colocalization of VSVG-GFP with TGN46 as early
as 1 h following the shift to 32°C (Fig. 6). BFA has been shown
to impede ER-to-Golgi apparatus transport (42), and cells
treated with BFA showed a dispersed Golgi apparatus, with
VSVG-GFP restricted to the ER, over the time course studied.
We conclude that both compounds 75 and 134 do not inhibit
ER-to-Golgi apparatus transport of VSVG-GFP, suggesting

that generalized anterograde transport mechanisms from the
ER to the Golgi apparatus remain unaffected.
To equally monitor compound effects on the secretory pathway beyond the Golgi apparatus, secretion of a GFP construct
bearing an amino-terminal NPY secretion signal (NPY-GFP)
was assessed qualitatively and quantitatively. During the process of secretion, a portion of NPY-GFP is maintained in a
compartment adjacent to and overlapping with the TGN (data
not shown). In contrast to BFA and compound 75, compound
134 had a minimal effect on NPY-GFP secretion as judged by
the immunofluorescence time course (see Fig. S4 in the supplemental material). Compound 75 partially impeded GFP
secretion from the TGN-associated compartment, as evidenced by the persistence of GFP fluorescence as long as 1 h
following cycloheximide treatment, at which time no GFPpositive cells were seen among control cells (see Fig. S4 in the
supplemental material). An ELISA was developed to quantitate the amounts of NPY-GFP secreted into the medium at
various time points following cycloheximide treatment (to inhibit new protein synthesis). Mean absorbance values for control wells containing DMEM alone were subtracted from
absorbance values for sample wells. Using this assay, we measured the effect of compound 134 (50 M) on GFP secretion.
The level of GFP secretion by compound 134-treated cells was
86% of that by control (untreated) cells at 1 h and 89% of that
by control cells at 2 h. (data not shown). Compound 75 (25
M) decreased post-Golgi secretion of NPY-GFP to 58% and
71% of that by control cells at 1 and 2 h, respectively (data not
shown).
DISCUSSION
Using a luciferase-based assay that was adapted to an HTS
for determining cell susceptibility to toxin-mediated inhibition
of protein synthesis, we have screened a chemical library of
small compounds and characterized two compounds that
showed marked potency and selectivity against intracellular
toxin transport. Both compounds demonstrated strong protective effects against Stx and ricin, and compound 75 was shown
to protect equally against DT. We thus report two novel compounds demonstrating efficacy against multiple bacterial toxins, with toxin IC50s nearly an order of magnitude greater than
those reported previously using knockdown approaches for
toxin inhibition (1, 8). More importantly, our results demonstrated that compounds 75 and 134 conferred toxin-protective
effects by disrupting transport at distinct steps along the toxintrafficking pathway.
Screens at the ICCB facility have recently identified smallmolecule inhibitors of Toxoplasma gondii invasion and Vibrio
cholerae virulence. From a library of 12,160 compounds, 24
inhibitors of Toxoplasma gondii invasion were identified (5).
These included compounds that inhibited host uptake of the
organism as well as inhibitors of Toxoplasma gliding motility
and microneme-based secretion. Effective doses of these compounds ranged from 3 to 100 M. Recently, a similar screen
identified a small-molecule inhibitor of Vibrio cholerae virulence (20). A total of 50,000 compounds were screened, and
109 compounds that inhibited virulence factor expression were
identified. Of these, a compound named virastatin inhibited
the transcriptional regulator ToxT, thereby suppressing the
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FIG. 4. Compounds 75 and 134 affect the trafficking of StxB through
the TGN. (A) A StxB construct containing a tandem of sulfation sites and
a histidine tag for purification (see Materials and Methods) was used to
track StxB transport through the TGN in Vero cells. (B) The degree of
sulfation of the StxB-Sulf2 construct was determined as described in Materials and Methods. % signal, band density relative to the band signal in
DMSO-treated cells from one representative experiment. Results are
representative of two similar experiments.
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expression of Ctx and the toxin-coregulated pilus. The MIC of
virastatin against Ctx expression ranged from 3 to 40 M,
depending on the bacterial strain. Thus, recent screens underscore the utility of small-molecule assays in the identification of
compounds that inhibit microbial virulence or block intracellular trafficking pathways.
Morphological analysis of compound-treated cells revealed dispersed Golgi apparatus-derived vesicles, but their pronounced
toxin-protective effects were distinct from those of apoptosisinducing or cytotoxic agents. The disrupted Golgi membranes

showed competent anterograde trafficking of VSVG-GFP and
secretion of NPY-GFP in compound 134-treated cells, implying
that this compound was preferentially targeting components of
the retrograde pathway. Similar Golgi apparatus fragmentation
has been observed in HeLa cells depleted of Cog3p, and the
disrupted Golgi membranes were equally capable of anterograde
trafficking of VSVG (65). Though it also exhibited a strong protective effect against toxin-mediated protein synthesis inhibition,
compound 75 appeared to have a more pronounced effect on the
post-Golgi trafficking of NPY-GFP. Nonetheless, the identifica-
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FIG. 5. Effects of compounds on Golgi structure are reversible. (A) Vero cells were treated with compound 75 (25 M), compound 134 (50
M), or BFA (25 g/ml) for 1 h at 37°C, followed by a wash with prewarmed medium and an additional incubation at 37°C in medium alone for
the indicated times. Cells were fixed, permeabilized, and stained with anti-giantin and anti-TGN46 antibodies. Control, cells treated with DMSO
(0.5% [vol/vol]) and fixed 2 h after washing as were compound-treated cells. Blue, nuclei. Images were obtained at ⫻1,000 magnification. (B) Vero
cells were pretreated with compounds for 1 h at 37°C, followed by a wash with prewarmed medium and an additional incubation at 37°C in medium
alone for 2 h. Cells were then treated with Stx for 4 h and assessed for levels of protein synthesis by using the radioactive amino acid incorporation
assay. Stx-response curves were generated as described in Materials and Methods. Black triangles, no treatment; gray squares, compound treatment
alone; gray open triangles, compound treatment with washout.
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informative chemical genetic method of studying intracellular
toxin transport in a controlled and reversible manner (58).
Pharmacological agents derived from small compounds have
enhanced our understanding of the biology of retrograde
transport and its implications for Golgi apparatus organization
(10). Retrograde flow through the Golgi apparatus is believed
to balance anterograde flow in order to establish a membrane
equilibrium while maintaining Golgi apparatus polarity (2, 36,
51). It has been suggested that components regulating retrograde trafficking of glycolipid toxin receptors could also serve
a role in the retrograde recycling of Golgi membranes (38, 61).
Indeed, it remains to be seen if the recycling of different
resident Golgi proteins is being directly or indirectly targeted
by protein toxins and, more importantly, whether the inhibitory
effects of either or both of these compounds are targeting this
host membrane recycling machinery. Future studies with covalently modified compounds will allow for the affinity purification of intracellular targets and the identification of host
components involved in these processes. The roles of these
intracellular targets in intracellular trafficking will elucidate
our understanding of toxin subversion of retrograde, membrane recycling pathways. As the mechanisms underlying endocytic transport become clearer, the ability to manipulate and
alter these pathways through small molecules will serve as an
invaluable tool in probing both the retrograde and anterograde
trafficking mechanisms.
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